Kareem Saad - Mar 16, 2024 Form 4 Insider Report for GeneDx Holdings Corp. (WGS)

Role
CHIEF TRANSFORMATION OFFICER
Signature
/s/ Devin Schaffer, Attorney-in-Fact
Stock symbol
WGS
Transactions as of
Mar 16, 2024
Transactions value $
-$21,269
Form type
4
Date filed
3/19/2024, 04:14 PM
Previous filing
Mar 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WGS Class A Common Stock Options Exercise $0 +5.11K +19.36% $0.00 31.5K Mar 16, 2024 Direct F1
transaction WGS Class A Common Stock Sale -$21.3K -2.01K -6.37% $10.59 29.5K Mar 18, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WGS Restricted Stock Unit Options Exercise $0 -5.11K -7.69% $0.00 61.4K Mar 16, 2024 Class A Common Stock 5.11K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2 The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.6501 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.